RESULTS. We present the current data from the first-line palbociclib cohort (N=53) where, median time to CNSm on was 24 months (interquartile range 13-46). Fifty-two (98.1%) patients had documented bone, 31 (58.5%) dural, 7 (13.2%) leptomeningeal, and 33 (62.3%) calvarial ...
At this point, the disease progresses in about half of patients,25,26 metastasizing to involve other organs, such as bone, and leading ultimately to death. Each of these phases requires different diagnostic, surveillance, and treatment modalities, all designed to calibrate treatment to disease risk...
The primary objective was the risk of CV event, with time to first CV event, defined as CV-related hospitalization, as the associated primary endpoint. Reasons for the first CV-related hospitalization were defined by the primary diagnosis (ICD-10-GM codes) for the first CV-related hospitalizati...
As an example, in 2013, there were 40,372 new cases of prostate cancer (ICD-10 C61) registered in England, the equivalent of 185.7 per 100,000 population. Patients with metastatic prostate cancer who have not previously received hormone therapy or are continuing to respond to hormone therapy ...
Patients with primary and bone metastatic breast cancer have significantly reduced survival and life quality. Due to the poor drug delivery efficiency of anti-metastasis therapy and the limited response rate of immunotherapy for breast cancer, effective treatment remains a formidable challenge. In this ...
Metastatic breast cancer was identified using ICD-9 diagnosis codes of 196.x to 198.x (excluding 198.2) and ICD-10 diagnosis codes of C77.x to C79.x (excluding C79.2). We classified patients as having metastatic breast cancer if at least 2 claims were found with these codes from 30 ...
Table S1. SABR clinical characteristics (N = 32 patients included in the translational part), related to Figures 1 and 3 and STAR Methods Table S5. Patient characteristics in the ABIMMUNE trial, the ARTIC trial and the Firenze lung cancer cohort, related to Figure 3 and STAR Methods Documen...
Bone 2 (0.3) 0 (0.0) 2 (1.0) Brain 5 (0.9) 4 (1.0) 1 (0.5) Melanoma 21 (3.6) 21 (5.5) 0 (0.0) Others* 199 (34.0) 122 (31.7) 77 (38.5) Initial cancer diagnosis⁎⁎, n (%)4 Stage III 135 (23.3) 83 (21.6) 52 (26.7) .1773 Stage IV 445 (76.7) 302 (78.4) 14...
2). Take the following case as an example: a 36-year-old married white patient with ER-positive (ER+) HER2 + MBC that had metastasized to the bone but not to the brain, liver, or lung was treated with chemotherapy but not surgery. In this case, the total nomogram scores for B...
bAdjusted for age, comorbidity status, pre-index corticosteroid use, as well as the following established metastatic castration-resistant prostate cancer prognostic variables: prostate-specific antigen, alkaline phosphatase, hemoglobin, and visceral and bone metastasis (ICD-9-CM: 197-199.1). Comorbidity ...